Investment Thesis
Korro Bio is a pre-revenue development-stage biopharmaceutical company with a fortress balance sheet ($61.7M cash, minimal debt) but zero commercial traction and substantial operating losses (-$20.4M annually, -$16.1M FCF). Financial viability depends entirely on successful drug development and FDA approvals, creating high execution risk despite adequate capital runway of 3.8+ years at current burn rate.
Strengths
- Strong cash position of $61.7M with only $180K debt provides adequate runway for development
- Excellent liquidity metrics (8.13x current ratio, 0.00x debt/equity) minimize near-term refinancing risk
- Substantial asset base of $183.6M suggests valuable intellectual property and research infrastructure
Risks
- Zero revenue indicates complete absence of commercial operations or product market acceptance
- Persistent operating losses (-$20.4M) and negative free cash flow (-$16.1M) require continuous capital burn with no offsetting revenue
- Success entirely contingent on drug development and FDA regulatory approval—inherently low probability outcomes in biotech with no visibility into pipeline quality
Key Metrics to Watch
- Revenue emergence and growth—any commercial product launch would fundamentally change risk profile
- Operating cash flow trend—declining burn rate would indicate progress toward profitability milestone
- Pipeline clinical trial results and regulatory milestones—FDA approvals or trial failures will drive company valuation
Financial Metrics
Revenue
0.0
Net Income
-19.6M
EPS (Diluted)
$-1.69
Free Cash Flow
-16.1M
Total Assets
183.6M
Cash
61.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-16.4%
ROA
-10.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.13x
Quick Ratio
8.13x
Debt/Equity
0.00x
Debt/Assets
34.8%
Interest Coverage
-71.96x
Long-term Debt
180.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T10:53:19.591522 |
Data as of: 2026-03-31 |
Powered by Claude AI